ADC Development Services for Brain Tumors

Antibody-drug couples (ADC) are a new class of highly effective biologic drugs formed by linking antibodies to biologically active drug components. This strategy of combining the high specificity of monoclonal antibody drugs with the high activity of small molecule cytotoxic drugs can improve the targeting and reduce the toxic effects of brain tumor drugs.

Figure 1. In vivo processing of a typical antibody drug conjugate. (Yiming, J., et al., 2022)

We provide ADC development services for brain tumors

While early ADC has limited success and high toxicity in brain tumor patients, Alfa Cytology is updating and improving ADC with the goal of lower immunogenicity and more payload. Our goal is to overcome the various factors affecting ADC targeting of brain tumors to improve their efficacy and therapeutic potential in brain tumors.

• Antibody screening services
  We use phage display and antibody humanization services to help identify, optimize, and humanize target-specific antibodies. Subsequently, internalized antibodies are screened by the Internalized Antibody Screening Service or by applying anti-antibody ADC.
• Drug linkage services
  Highly toxic cytotoxins are used as payloads in ADC. The payload is typically first coupled to the junction to form a drug-junction complex and then coupled to the antibody via compatible coupling chemistry. While the payload determines the nature of the pharmacological action, the junction regulates the payload release mechanism within the cancer cell. We can help you design, optimize and synthesize drug-junction complexes for optimal results.
• Antibody design and coupling services
  Antibody sequences can be modified to accommodate the insertion of specific binding sites such as additional cysteine residues, selenocysteine, unnatural amino acids, and proteoglycan chains on the Fc region can also be easily modified by glycosyl substitution. The modified antibodies are conjugated to drug-junction complexes to form ADC and can be characterized.
• ADC in vitro analysis
  Before proceeding to the vivo evaluation phase, the in vitro efficacy of the ADC must be demonstrated. The analysis we provide consists of basic biochemical analysis and the vitro efficacy analysis. These include target affinity testing, internalization analysis, cytotoxicity analysis, antibody-dependent cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) analysis, and drug/antibody ratio (DAR) determination.
• ADC in vivo analysis
  The final stage of preclinical ADC development is the evaluation of its in vivo efficacy and pharmacokinetics, including its distribution, metabolism, and catabolic profile. Finally, we will also evaluate the safety of the ADC.

The ultimate goal of the strategy offered by Alfa Cytology is to maximize the therapeutic potential of ADC by enabling penetration through the blood-brain barrier and selecting more biologically relevant targets, new drug targeting approaches, and newer payloads in the brain and its microenvironment. Please feel free to contact us to learn more about how we can serve you. We are always working toward a more promising tomorrow for brain tumor patients.

Reference

1. Yiming, J., et al. (2022). “Stepping forward in antibody-drug conjugate development.” Pharmacology & Therapeutics, 229.